← Browse by Condition
Medical Condition

pdac pancreatic ductal adenocarcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for pdac pancreatic ductal adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pdac pancreatic ductal adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for pdac pancreatic ductal adenocarcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for pdac pancreatic ductal adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pdac pancreatic ductal adenocarcinoma?
pdac pancreatic ductal adenocarcinoma research spans Phase 1 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pdac pancreatic ductal adenocarcinoma clinical trial?
Eligibility criteria for pdac pancreatic ductal adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Top Sponsors
Alterome Therapeutics, Inc. 1 trial
I-Mab Biopharma US Limited 1 trial
IHU Strasbourg 1 trial

Recruiting Clinical Trials

NCT06835569 Phase 1
Recruiting

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Enrollment
188 pts
Location
United States
Sponsor
Alterome Therapeutics, Inc.
View Trial →
NCT04900818 Phase 1
Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Enrollment
330 pts
Location
United States, China
Sponsor
I-Mab Biopharma US Limited
View Trial →
NCT06666803
Recruiting

Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)

Enrollment
60 pts
Location
France
Sponsor
IHU Strasbourg
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology